Q4 EPS Estimates for Zimmer Biomet Raised by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Stock analysts at Zacks Research raised their Q4 2024 EPS estimates for shares of Zimmer Biomet in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.29 per share for the quarter, up from their prior forecast of $2.26. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.13 EPS and Q1 2026 earnings at $2.28 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.65 earnings per share.

A number of other equities analysts have also weighed in on the stock. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Truist Financial lifted their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Finally, UBS Group dropped their target price on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Trading Up 0.7 %

Shares of ZBH stock opened at $110.96 on Monday. The company has a market capitalization of $22.09 billion, a P/E ratio of 21.10, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The business’s 50 day moving average is $106.86 and its two-hundred day moving average is $109.54. Zimmer Biomet has a twelve month low of $101.47 and a twelve month high of $133.90.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently bought and sold shares of ZBH. Dunhill Financial LLC boosted its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank purchased a new stake in shares of Zimmer Biomet during the third quarter worth about $31,000. Family Firm Inc. acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $33,000. Finally, Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.